Somatostatin analogue for acromegaly (lanreotide first-generation SSA; pasireotide for SSA-refractory disease)
Vista determinista de la entidad fuente YAML. La autoridad clínica sigue con los ID de fuente citados y estado de firma del revisor.
Registro de base de conocimiento para la auditoría. Contenido clínico provisional: esto no es una prescripción. Un oncólogo debe verificar fuentes originales, aplicabilidad y estado de revisión.
Fuente YAML: registro completo
| Componentes | DRUG-LANREOTIDE |
|---|
| ID | REG-SSA-ACROMEGALY |
|---|---|
| Tipo | Esquema terapéutico |
| Situación | reviewed 2026-07-11 | pending_clinical_signoff |
| Enfermedades | Ninguna declarada |
| Fuentes | SRC-NCCN-CNS-2025 SRC-NCCN-NET-2025 |
Notas
STUB pending clinical co-lead signoff (CHARTER §6.1). Lanreotide modeled as the representative first-generation SSA per the Disease narrative ("somatostatin analogs (octreotide LAR, lanreotide, pasireotide LAR)"), mirroring the identical modeling choice already made in REG-LANREOTIDE-AUTOGEL-GI-NET / ALGO-PNET-METASTATIC-1L / ALGO-GI-NET-ADVANCED-1L. Octreotide LAR is an equivalent alternative first-generation SSA but DRUG-OCTREOTIDE does not yet exist in this KB (previously flagged as a deferred item in those sibling algorithms) — not authored here to stay within this task's scope; open gap noted on DIS-PITUITARY-ADENOMA.
Utilizado por
Indicación
IND-PITUITARY-ADENOMA-1L-ACROMEGALY-SURGERY-SSA- IND-PITUITARY-ADENOMA-1L-ACROMEGALY-SURGERY-SSA